A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.

ABSTRACT: Oncogenic activation of RAS genes via point mutations occurs in 20%-30% of human cancers. The development of effective RAS inhibitors has been challenging, necessitating new approaches to inhibit this oncogenic protein. Functional studies have shown that the switch region of RAS interacts with a large number of effector proteins containing a common RAS-binding domain (RBD). Because RBD-mediated interactions are essential for RAS signaling, blocking RBD association with small molecules constitutes an attractive therapeutic approach. Here, we present evidence that rigosertib, a styryl-benzyl sulfone, acts as a RAS-mimetic and interacts with the RBDs of RAF kinases, resulting in their inability to bind to RAS, disruption of RAF activation, and inhibition of the RAS-RAF-MEK pathway. We also fi

SUBMITTER: Athuluri-Divakar SK 

PROVIDER: S-EPMC5006944 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature